Thymosin α 1 activates dendritic cells for antifungal Th1 resistance through Toll-like receptor signaling

Blood

Volumn 103, Issue 11, 2004, Pages 4232-4239

  Romani, Luigina ^a   Bistoni, Francesco ^b   Gaziano, Roberta ^b   Bozza, Silvia ^b   Montagnoli, Claudia ^b   Perruccio, Katia ^b   Pitzurra, Lucia ^b   Bellocchio, Silvia ^b   Velardi, Andrea ^b   Rasi, Guido ^b   Di Francesco, Paolo ^b   Garaci, Enrico ^b  

^a UNIVERSITY OF PERUGIA   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

A 2942; AMPHOTERICIN B; CYCLOPHOSPHAMIDE; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 12; MITOGEN ACTIVATED PROTEIN KINASE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; THYMOSIN ALPHA1; THYMUS PEPTIDE; TOLL LIKE RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; BONE MARROW CELL; CELL DIFFERENTIATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; FEMALE; FUNGUS IMMUNITY; IMMUNITY; LUNG; MOUSE; NERVE CELL PLASTICITY; NONHUMAN; PRIORITY JOURNAL; TH1 CELL;

EID: 2542451903     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2003-11-4036     Document Type: Article

References (50)

1. Denning DW. Aspergillus. In: Mandel GL, Bennett JE, Dolin R, eds. Principles and Practice of Infectious Diseases. Philadelphia, PA: Saunders; 2000:2674-2682.
2. Marr KA, Carter RA, Boeckh M, Martin P, Corey L. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood. 2002;100:4358-4366.
3. Patterson TF, Kirkpatrick WR, White M, et al. Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. Medicine. 2000;79:250-260.
4. BitMansour A, Burns SM, Traver D, et al. Myeloid progenitors protect against aspergillosis and Pseudomonas aeruginosa infection following hematopoietic stem cell transplantation. Blood. 2002;100:4660-4667.
5. Hebart H, Bollinger C, Fisch P, et al. Analysis of T-cell responses to Aspergillus fumigatus antigens in healthy individuals and patients with hematological malignancies. Blood. 2002;100:4521-4527.
6. Grazziutti ML, Rex JH, Cowart RE, Anaissie EJ, Ford A, Savary CA. Aspergillus fumigatus conidia induce a Th1-type cytokine response. J Infect Dis. 1997;176:1579-1583.
7. Cenci E, Mencacci A, Bacci A, et al. T cell vaccination in mice with invasive pulmonary aspergillosis. J Immunol. 2000;165:381-388.
8. Garlanda C, Hirsch E, Bozza S, et al. Non-redundant role of the long pentraxin PTX3 in anti-fungal innate immune response. Nature. 2002;420:182-186.
9. Grazziutti M, Przepiorka D, Rex JH, Braunschweig I, Vadhan-Raj S, Savary CA. Dendritic cell-mediated stimulation of the in vitro lymphocyte response to Aspergillus. Bone Marrow Transplant. 2001;27:647-652.
10. Bozza S, Gaziano R, Spreca A, et al. Dendritic cells transport conidia and hyphae of Aspergillus fumigatus from the airways to the draining lymph nodes and initiate disparate Th responses to the fungus. J Immunol. 2002;168:1362-1371.
11. Bozza S, Gaziano R, Lipford GB, et al. Vaccination of mice against invasive aspergillosis with recombinant Aspergillus proteins and CpG oligodeoxynucleotides as adjuvants. Microbes Infect. 2002;4:1281-1290.
12. Wang JE, Warris A, Ellingsen EA, et al. Involvement of CD14 and toll-like receptors inactivation of human monocytes by Aspergillus fumigatus hyphae. Infect Immun. 2001;69:2402-2406.
13. Mambula SS, Sau K, Henneke P, Golenbock DT, Levitz SM. Toll-like receptor (TLR) signaling in response to Aspergillus fumigatus. J Biol Chem. 2002;277:39320-39326.
14. Steinman RM, Pope M. Exploiting dendritic cells to improve vaccine efficacy. J Clin Invest. 2002;109:1519-1526.
15. Gallucci S, Lolkema M, Matzinger P. Natural adjuvants: endogenous activators of dendritic cells. Nat Med. 1999;5:1249-1255.
16. Ibrahim MA, Gotch FM. Making smarter immunotherapies (letter). Nat Immunol. 2000;1:3.
17. Goldstein AL, Guha A, Zatz MM, Hardy MA, White A. Purification and biological activity of thymosin, a hormone of the thymus gland. Proc Natl Acad Sci U S A. 1972;69:1800-1803.
18. Billich A. Thymosin alpha1, SciClone Pharmaceuticals. Curr Opin Investig Drugs. 2002;3:698-707.
19. Rasi G, DiVirgilio D, Mutchnick MG, et al. Combination thymosin alpha 1 and lymphoblastoid interferon treatment in chronic hepatitis C. Gut. 1996;39:679-683.
20. Wara DW, Goldstein AL, Doyle NE, Amman AJ. Thymosin activity in patients with cellular immunodeficiency. N Engl J Med. 1975;292:70-74.
21. Garaci E, Pica F, Rasi G, Favalli C. Thymosin alpha 1 in the treatment of cancer: from basic research to clinical application. Int J Immunopharmacol. 2000;22:1067-1076.
22. Bistoni F, Marconi P, Frati L, Bonmassar E, Garaci E. Increase of mouse resistance to Candida albicans infection by thymosin al. Infect Immun. 1982;36:609-614.
23. Sodhi A, Paul S. Involvement of mitogen-activated protein kinases in the signal transduction pathway of bone marrow-derived macrophage activation in response to in vitro treatment with thymosin alpha 1. Int Immunopharmacol. 2002;2:47-58.
24. Giuliani C, Napolitano G, Mastino A, et al. Thymosin-alphal regulates MHC class I expression in FRTL-5 cells at transcriptional level. Eur J Immunol. 2000;30:778-786.
25. Mencacci A, Perruccio K, Bacci A, et al. Defective anti-fungal T-helper 1 (TH1) immunity in a murine model of allogeneic T-cell-depleted bone marrow transplantation and its restoration by treatment with TH2 cytokine antagonists. Blood. 2001;97:1483-1490.
26. Kadowaki N, Ho S, Antonenko S, et al. Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens. J Exp Med. 2001;194:863-869.
27. Latz E, Schoenemeyer A, Visintin A, et al. TLR9 signals after translocating from ER to CpG DNA in the lysosome. Nat Med. 2004;5:190-198.
28. Sweet MJ, Campbell CC, Sester DP, et al. Colony-stimulating factor-1 suppresses responses to CpG DNA and expression of toll-like receptor 9 but enhances responses to lipopolysaccharide in murine macrophages. J Immunol. 2002;168:392-399.
29. Chen CH, Zhang DH, La Porte JM, Ray A. Cyclic AMP activates p38 mitogen-activated protein kinase in Th2 cells: phosphorylation of GATA-3 and stimulation of Th2 cytokine gene expression. J Immunol. 2000;165:5597-5605.
30. Siegal FP, Kadowaki N, Shodell M, et al. The nature of the principal type I interferon-producing cells in human blood. Science. 1999;284:1835-1837.
31. Akira S, Takeda K, Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol. 2001;2:675-680.
32. Schnare M, Barton GM, Holt AC, Takeda K, Akira S, Medzhitov R. Toll-like receptors control activation of adaptive immune responses. Nat Immunol. 2001;2:947-950.
33. Lin YZ, Yao SY, Veach RA, Torgerson TR, Hawiger J. Inhibition of nuclear translocation of transcription factor NF-kappa B by a synthetic peptide containing a cell membrane-permeable motif and nuclear localization sequence. J Biol Chem. 1995;270:14255-14258.
34. Singh RP, Dhawan P, Golden C, Kapoor GS, Metha KD. One-way cross-talk between p38 (MAPK) and p42/44 (MAPK): inhibition of p38 (MAPK) induces low density lipoprotein receptor expression through activation of the p42/44 (MAPK) cascade. J Biol Chem. 1999;270:19593-19600.
35. Edwards AD, Manickasingham SP, Spom R, et al. Microbial recognition via Toll-like receptor-dependent and -independent pathways determines the cytokine response of murine dendritic cell subsets to CD40 triggering. J Immunol. 2002;169:3652-3660.
36. Gilliet M, Boonstra A, Paturel C, et al. The development of murine plasmacytoid dendritic cell precursors is differentially regulated by FLT3-ligand and granulocyte/macrophage colony-stimulating factor. J Exp Med. 2002;195:953-958.
37. Dziarski R, Wang Q, Miyake K, Kirshning CJ, Gupta D. MD-2 enables Toll-like receptor 2 (TLR2)-mediated responses to lipopolysaccharide and enhances TLR2-mediated responses to Gram-positive and Gram-negative bacteria and their cell wall components. J Immunol. 2001;166:1938-1944.
38. Grottesi A, Sette M, Palamara AT, Rotilio G, Garaci E, Paci M. The conformation of peptide thymosin α 1 in solution and in membrane-like environment by circular dicroism and NMR spectroscopy: a possible model for its interaction with the lymphocyte membrane. Peptides. 1998;19:1731-1738.
39. Romani L, Bistoni F, Puccetti P. Fungi, dendritic cells and receptors: a host perspective of fungal virulence. Trends Microblol. 2002;10:508-514.
40. Baumann CA, Badamchian M, Goldstein AL. Thymosin alpha 1 is a time and dose-dependent antagonist of dexamethasone-induced apoptosis of murine thymocytes in vitro. Int J Immunopharmacol. 2000;22:1057-1066.
41. Rinaldi Garaci C, Favalli C, Del Gobbo V, Garaci E, Jaffe BM. Is thymosin action mediated by prostaglandin release? Science. 1983;220:1163-1164.
42. Zav'Yalov VP, Zav'Yalova GA. Interferons alpha/ beta and their receptors: place in the hierarchy of cytokines. APMIS. 1997;3:161-186.
43. Mellmann I, Steinman RM. Dendritic cells: specialized and regulated antigen-processing machines. Cell. 2001;106:255-258.
44. Okada T, Lian ZX, Naiki M, Ansari AA, Ikehara S, Gershwin ME. Murine thymic plasmacytoid dendritic cells. Eur J Immunol. 2003;33:1012-1019.
45. Sarandeses CS, Covelo G, Diaz-Jullien C, Freire M. Prothymosin alpha is processed to thymosin alpha 1 and thymosin alpha 11 by a lysosomal asparaginyl endopeptidase. J Biol Chem. 2003;273:13286-13293.
46. Lund J, Sato A, Akira S, Medzhitov R, Iwasaki A. Toll-like receptor 9-mediated recognition of Herpes simplex virus-2 by plasmacytoid dendritic cells. J Exp Med. 2003;198:513-520.
47. Cella M, Facchetti F, Lanzavecchia A, Colonna M. Plasmacytoid dendritic cells activated by influenza virus and CD40L drive a potent TH1 polarization. Nat Immunol. 2000;1:305-310.
48. Dalod M, Salazar-Mather TP, Malmgaard L, et al. Interferon α/ β and interleukin 12 responses to viral infections: pathways regulating dendritic cell cytokine expression in vivo. J Exp Med. 2002;195:517-528.
49. Rossi M, Arpinati M, Rondelli D, Anasetti C. Plasmacytoid dendritic cells: do they have a role in immune responses after hematopoietic cell transplantation? Hum Immunol. 2002;63:1194-1200.
50. Knutsen AP, Freeman JJ, Mueller KR, Roodman ST, Bouhasin JD. Thymosin-alpha1 stimulates maturation of CD34+ stem cells into CD3+4+ cells in an in vitro thymic epithelia organ coculture model. Int J Immunopharmacol. 1999;21:15-26.